Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has issued an announcement.
Clarity Pharmaceuticals has issued 1,913,041 fully paid ordinary shares following the exercise of options, without requiring disclosure to investors under the Corporations Act. This move reflects the company’s compliance with relevant legal provisions and indicates a strategic financial maneuver that could impact its market operations and investor relations.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company specializing in the development of innovative radiopharmaceuticals for treating serious diseases. The company is a leader in targeted copper theranostics, utilizing its SAR Technology Platform to develop treatments for cancer in both children and adults.
Average Trading Volume: 3,020,484
Technical Sentiment Signal: Sell
Current Market Cap: A$810.1M
See more data about CU6 stock on TipRanks’ Stock Analysis page.